NASDAQ$TRAW
Traws Pharma Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in endometrial cancer and reported third quarter 2022 financial results.
Onconova Therapeutics reported its Q3 2022 financial results, highlighting the upcoming Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). The company's cash and cash equivalents are expected to fund operations into 2024.
- Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC) is expected to start in 1Q23, with preliminary data expected in 4Q23.
- Rigosertib's investigator-sponsored studies have complemented efforts in the narazaciclib program, with recent data showing complete and partial responses in advanced KRAS-mutated non-small cell lung cancer when combined with a PD-1 checkpoint inhibitor.
- Cash and cash equivalents as of September 30, 2022, were $42.6 million, expected to fund operations into 2024.
- Net loss for the third quarter of 2022 was $5.4 million, or $0.26 per share.
Headline financials
Revenue & EPS history
Onconova · Revenue · Quarterly
$57K
Forward guidance
Onconova expects that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-0.7%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-5.0%
Avg return
30 days after
25%
9 / 36 earnings
Positive
+22.6%
Q3 2025
Best reaction
-22.6%
Q4 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +15.3% | — | — | |
| Q4 2026 | -22.6% | -12.6% | +18.2% | |
| Q3 2025 | +22.6% | +19.2% | +31.6% | |
| Q2 2025 | -1.2% | -18.3% | +16.5% | |
| Q1 2025 | -3.6% | +1.4% | +2.1% | |
| Q4 2024 | +6.0% | -1.0% | -30.5% | |
| Q3 2024 | -11.7% | -16.8% | -17.7% | |
| Q2 2024 | -2.7% | +5.4% | -5.4% | |
| Q1 2024 | -2.5% | -1.5% | -9.1% | |
| Q4 2023 | -1.5% | -19.8% | -34.7% | |
| Q3 2023 | -3.1% | +0.0% | +15.4% | |
| Q2 2023 | -2.0% | -11.2% | -20.4% | |
| Q1 2023 | -4.0% | -5.3% | +53.3% | |
| Q4 2022 | -3.9% | -5.3% | +51.3% | |
| Q3 2022 | +18.3% | +36.6% | +7.0% | |
| Q2 2022 | +3.9% | -1.6% | -10.1% | |
| Q1 2022 | -1.6% | -2.1% | -26.1% | |
| Q4 2021 | +10.0% | +13.7% | +0.6% | |
| Q3 2021 | +1.2% | -1.5% | -18.3% | |
| Q2 2021 | -4.4% | -11.8% | -1.2% | |
| Q1 2021 | -3.1% | -9.0% | -26.4% | |
| Q4 2020 | +0.0% | -3.6% | -97.0% | |
| Q3 2020 | +0.0% | +3.8% | +42.3% | |
| Q2 2020 | -3.6% | -6.4% | -79.1% | |
| Q1 2020 | +0.0% | +5.6% | +69.4% | |
| Q3 2019 | -7.1% | -16.7% | -35.7% | |
| Q2 2019 | -2.1% | -5.6% | +7.3% | |
| Q1 2019 | -6.3% | -11.5% | -15.9% | |
| Q3 2018 | -11.5% | -3.1% | -25.1% | |
| Q2 2018 | -9.1% | -6.8% | +11.4% | |
| Q1 2018 | -5.4% | -2.7% | +40.5% | |
| Q3 2017 | -2.1% | -16.8% | -22.1% | |
| Q2 2017 | -0.5% | -16.7% | -19.3% | |
| Q1 2017 | -0.5% | -0.5% | -9.0% | |
| Q3 2016 | +11.0% | +28.7% | -15.8% | |
| Q2 2016 | +2.5% | +4.2% | -21.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro